Metizolam Stats & Data

Metizolam was first patented in 1995 by a Japanese pharmaceutical company as a potential medication for treating anxiety disorders. Despite this early patent, the compound was never developed for clinical use and has no documented history of medical application. The substance emerged on the designer drug market in September 2015, when it began to be sold as a grey area research chemical through online vendors. Prior to this commercial availability, metizolam had little to no documented history of human use, making it one of many novel thienodiazepines to appear on the research chemical market with minimal pharmacological characterization in humans.

The toxicity and long-term health effects of recreational metizolam use have not been studied in any scientific context and the exact toxic dosage is unknown. This is because metizolam is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried metizolam suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.